Vasopressor Agents in Pulmonary Hypertension Crisis

Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring

Inclusion Criteria: 1. Age \> 18 years old; 2. Signed informed consent form; 3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH); 4. Presenting with manifestations of pulmonary hypertensive crisis; 5. Receiving both diagnosis and treatment in-hospital; 6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment. Exclusion Criteria: 1. At SCAI stage D or stage E ; 2. Patients who only receive a diagnosis but no treatment in the hospital; 3. Uncontrolled hyperthyroidism; 4. Complicated with angle-closure glaucoma; 5. Hypersensitivity to the study drug; 6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane; 7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide); 8. Pregnancy; 9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.